IDO1 and neoplasm: Therefore, this study aimed to investigate the impact of IDO1 expression, PD-L1 expression, CD8+ tumor-infiltrating lymphocyte (TIL) status, and their combination on pathologic response and recurrence in EC patients who underwent neoadjuvant CRT.